Biodesix
Kieran O’Kane has over 20 years’ experience in the diagnostic and biotech industries.
Kieran joined Biodesix in 2018 as Head of Strategic Marketing and Corporate Development, before being promoted to Chief Commercial Officer in March 2020. He has played a critical role in establishing Biodesix as a leader in the development of blood-based diagnostic solutions for lung diseases, leading the successful acquisition of Integrated Diagnostics (Indi) and Oncimmune’s laboratory and incidental pulmonology nodule malignancy test. Additionally, Kieran led his team to successfully launch the Nodify XL2TM and Nodify CDTTM tests for Biodesix.
Prior to joining the company, Kieran held a variety of commercial roles of increasing responsibility at companies such as Nanostring, BMS and Roche Pharmaceuticals.
Kieran holds a B.Sc. (Hons) degree in Pharmacology from King’s College, London.
This person is not in any offices
Biodesix
3 followers
Working alongside physicians, we solve complex diagnostic challenges from early diagnosis of lung nodules through late stage cancer.